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Abstract
Background Pelvic organ prolapse (POP) negatively affects many women’s quality of life. The ability to develop improved
therapeutic approaches for POP patients is hampered by low patient recruitment and retention rates in clinical trials.
Objective Our objective was to explore the motivational factors and barriers to recruitment and participation in clinical trials
among postmenopausal women with POP who are intending to have surgical management.
Design Qualitative study based on in-depth face-to-face interviews with postmenopausal women attending urogynaecology
clinics in the UK intending to have surgical management for pelvic organ prolapse. These women were eligible to participate
in the on-going clinical trial on the use of local vaginal oestrogen as an adjunct to surgical treatment. Twenty-two postmenopausal
women aged 52–76 years were interviewed. Interviews were analysed using thematic analysis method.
Results Many women participated because of altruistic motivations; however, we found that clarity of information provided,
timing of approach and acceptability of study design played a pivotal role in women. Of the women who declined participation,
the following themes emerged: uncertainty of the investigational product, fear of experimentation, logistical concerns and regret
that their condition was trivialised at an early stage.
Conclusion We have gained a valuable insight into women’s views and experience in the decision making process.
Understanding the elements that will enhance trial participation such as clarity of information provided, balance between
professional guidance whilst maintaining equipoise, easy access to trial teams and timing of approach will ultimately enable
us to improve our recruitment to clinical trials.
Keywords Postmenopausal women . Oestrogen . Qualitative design
Introduction
Pelvic organ prolapse is a chronic condition affecting millions
of women. The condition negatively impacts on their quality
of life through effects on their urinary and bowel symptoms,
body image and chronic backache [1]. The severity of symp-
toms is not, however, correlated with the level of POP.
Women are offered varied treatment options from expectant,
conservative and surgical management.
One of the main recommendations of the UK government
Life Science Strategy was for the National Health services
(NHS) to respond to the growing readiness of patients to par-
ticipate in research studies [2]. The strategy recommended
researchers to respond to patient choices to enhance participa-
tion within a trial. However, there is extensive evidence from
the NHS acute hospital sector that poor patient recruitment or
retention of patients to clinical research is widespread, leading
Trial registration number: ISRCTN46661996.
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to delays in commencement or completion of both academic
and commercially funded research [3]. This results in wastage
of public resources and opportunities for patient participation.
We performed a study to assess the feasibility of patient
screening and recruitment process to study the effectiveness of
Local Oestrogen Treatment in Postmenopausal Women
Undergoing Pelvic Organ Prolapse Surgery (LOTUS)
https://doi.org/10.1186/ISRCTN46661996. This study was
in preparation for a large definitive randomised controlled
study to determine whether pre- and postoperative local
oestrogen treatment is more effective in improving prolapse-
related patient-reported outcomes and reducing recurrence of
prolapse symptoms when compared to no treatment.
The research team identified the women eligible to partic-
ipate in the feasibility trial by screening the GP referral letters.
Potential eligible women were sent patient information leaf-
lets before the clinic appointments in order to give the women
an opportunity to consider participation in the clinical trial.
The trial team comprised of a research fellow, research nurses
and urogynaecologist from district and tertiary hospitals
across the UK. Once eligibility was reconfirmed, women were
given sufficient time to obtain informed written consent and
collect baseline data. Randomisation was performed using a
web-based central randomisation system (via Birmingham
Clinical Trials Unit) to allocate patients to either oestrogen
or no treatment in a 1:1 ratio. Minimisation was used to
achieve balance between age (< 65 years or ≥ 65 years), parity
(≤ 2 or > 2 vaginal births) and maximum stage of prolapse (I,
II or III/IV).
Women allocated to oestrogen (oestradiol hemihydrate 10
mcg vaginal pessaries; Vagifem™, Novo Nordisk) were
instructed to use the oestrogen pessaries 6 weeks prior to sur-
gery (once daily for 2 weeks and twice weekly for 4 weeks) up
to the night before surgery. Treatment was restarted 6 weeks
postoperatively, administering twice weekly for 20 weeks.
Women were encouraged to insert the pessaries into the vagi-
na at the same time of day. However, if a dose was missed,
patients were advised it should be administered as soon as
possible thereafter, provided the next dose was not due.
Participants allocated no treatment received the usual care of
the randomising centre. The surgical approach to POP repair
was at the discretion of the urogynaecological surgeon. The
researchers conducting the qualitative interviewswere blinded
to the participant’s intervention allocation within the study.
Approximately quarter of women opt for surgical repair of
POP [4]. There are few studies seeking to explore the experi-
ence of postmenopausal women with POP planning on under-
going surgical repair. Therefore, alongside the LOTUS feasi-
bility study, we undertook a qualitative study with the objec-
tive of exploring the factors that motivate this group of women
to participate in clinical trials. Some women see POP as a
sensitive and embarrassing condition; therefore, to prepare
for our planned future trial, we aimed to identify barriers to
recruitment and participation in clinical trials among postmen-
opausal women with pelvic organ prolapse intending to have
surgical management.
Methods
We conducted semi-structured, in-depth, audio-recorded in-
terviews with postmenopausal women eligible to participate
in the LOTUS study (Table 1). Interviews were conducted
from October 2015 until July 2016 from Birmingham
Women’s and Children’s NHS Foundation Trust. The re-
search team proposed a priori sample size at the time of initial
proposal of ten interviews with a further stopping criterion of
five interviews. The essence of these interviews was to obtain
information and shared beliefs until data saturation was
achieved [5–8]. The research team ultimately interviewed 22
women individually. Along with this a focused group inter-
view (10 women) was used to expand on and verify the
emerging themes from individual themes.
Of the 22 women interviewed, 7 who had initially declined
participation in the LOTUS trial were willing to take part in
the qualitative arm of the study. Participation in the qualitative
arm of the study was purely voluntary among those who par-
ticipated or declined participation in the LOTUS trial. The
study aimed for a diverse, maximum variation sample of par-
ticipants. Participants were sent a patient information sheet,
had the study explained to them and signed a consent form
before the interview. The women who consented to participate
in the qualitative arm of the study were given the choice of
place where theywould prefer to have the interview in order to
make sure that the women were most comfortable and free to
voice their thoughts. Women were interviewed in informal
non-clinical settings such as quiet rooms in hospitals or at
the comfort of their own homes via teleconference sessions.
This allowed the women to chose the most convenient time
and place; therefore, they never felt pressured or rushed. The
interview had two parts:
& An unstructured narrative section, in which participants
were asked to tell their own story with as little interruption
as possible, to capture their own accounts of their experi-
ence with POP, what brought them to the hospital and
aspects of the trial that they felt were important to them.
& A series of prompts, used by the interviewer to explore
particular issues further in a semi-structured part of the
interview
The interviews lasted 45 to 90 min each. The interviews
were transcribed verbatim and analysed thematically using the
organisational support of NVivo 10 software. Transcripts
were read and re-read carefully by the interviewer, and a cod-
ing framework was developed. A second researcher checked
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the transcripts (LL) and independently coded the first few
interviews; results were compared and discussed. The coding
framework was revised and further developed. A qualitative
interpretative approach was utilised, combining thematic anal-
ysis with constant comparison continuously looking for antic-
ipated and emergent themes [6, 7]. Field notes weremade after
every interview process in order for the interviewer to capture
the understanding and body language aspects of patient during
the interview when talking on certain aspects of the condition
and the trial. A modified grounded theory approach using the
“one sheet of paper” method ensured that all the coded ex-
tracts within the theme were included and compared in the
analysis. The approach ensured that every instance and nuance
was considered importantly including deviant cases.
Qualitative data collection and analysis often proceed itera-
tively to achieve data saturation, with analytic categories sat-
urated when data from new interviews do not add any more to
the analysis [6, 7].
Results
Twenty-two women with symptomatic POP were recruited
for the qualitative study. Symptomatic POP was defined as
Table 1 Qualitative Interview
guide Regarding pelvic organ prolapse When did you first start experiencing symptoms of prolapse?
• How did it affect your day-to-day life?
• What did you understand about prolapse
• When were you diagnosed?
• How did you feel about the diagnosis?
• Did you try another treatment?
Tell me about your experiences of using pessaries/ physiotherapy for
prolapse
• How effective was this treatment?
Views on Medical Trials [General] What do you think about medical trial?
• for individuals?
• for medical science?
What do you think about randomisation?
• Understandings of randomisation/how treatment is allocated
• Is randomisation acceptable to you?
• Is the possibility of not getting treatment acceptable?
Views on participation in LOTUS
study
What are your thoughts about the trial?
• NB: Expand into an open-ended discussion about the trial
° Hopes for the trial
° Concerns about the trial
What would motivate/motivated you to take part in the trial? What
would you hope to get out of participating in this study?
What are your main concerns about participating in the trial?
• What would be a barrier to you participating?
° Personal factors?
• Past experiences with treatments or trials
• Time or travel costs
° Trial factors?
• Concerns about treatment availability
• Concerns about treatment choice and randomisation
What did you think about the study after reading the patient
information leaflet for the study?
° Did you feel the leaflet gave you enough information?
Experiences of hormone
replacement treatment (HRT)
What do you understand by HRT:
• Have you used HRT before? For how long?
• Do you have any concerns regarding HRT?
•Have used oestrogen pessaries or creams in the past? Which would you
prefer to use?
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presence of a vaginal bulge and/or other symptoms from the
bladder or bowel. The women were assessed using the POP-Q
classification system [9]. Recruitment was according to pur-
posive sampling, i.e., the greatest variation of characteristics
such as age, parity, BMI and stage of prolapse in order to
capture wide narratives from the informants (Table 2). The
results are summarised in Table 3.
Factors that facilitated recruitment
Theme 1: probably help another woman
Themajority of women who were approached to participate in
the LOTUS trial were willing, as they wanted to help other
women and hoped that their contribution and/or participation
would help other women in their similar situation.
Interestingly, it was the group of women who had struggled
for many years with prolapse who readily wanted to partici-
pate rather than those who received a new diagnosis. The
women who declined regretted that they did not request to
be seen at tertiary care earlier and felt that primary care did
not offer them much help with their symptoms.
P3: As I sat in the waiting room just looking at the trial
poster and after reading through the leaflet, there was this
inclining in me to participate, I have had just enough with
my symptoms, if I can participate in this trial and if it would
help another woman I would be really happy.
P5: I’m retired now and I have participated in other trials
and I think this study really makes sense, I think this will make
a change for the future generation.
P6: I am 76 years old and suffered with a prolapse for so
many years, I know ageing is a process and having a prolapse
may be part of it, but I think more women should talk about
it…These are present day problems and studies like this will
start conversations, which I think is essential. You do not often
hear women’s hour talking about vaginal prolapse (laughs).
Yes, I would definitely take part, I hope the study triggers
women to talk more about vaginal prolapse, this should help.
P11: I wish I did not carry on with these pelvic exercises,
now the gynaecologist offers me surgery. There should be
some time limits in place. My doctor examined me once and
no further, perhaps I could have avoided surgery! I rather just
get on have surgery with no further delays in my treatment.
Theme 2: Easy to understand protocol and research team
accessibility
This study reinforces that clear and easy to understand proto-
cols played a vital role in encouraging women to participate in
the study. Reading and understanding a study consent form
has been shown to be critical to enrolment in a trial. The
women within the study felt that they had the ability to access
the trial team at any point during the study and felt reassured.
This was a safety net that many of them felt convinced would
help them through the process without just becoming a trial
number to the research. Many felt that interaction between
themselves and the trial team gave them the confidence to
complete the trial from start to end.
P12: I received the leaflet prior to me coming for my ap-
pointment; it was quite straightforward and simple. I had a
few questions, which the researcher answered for me.
P10: The clinician made it very easy for me to understand
the process; we had a really long chat. I was able to make my
mind very easily. I trust the team here, no matter how many
times I asked questions the team were very approachable. The
clinic appointment took nearly 45 min but they put the effort in
making sure that I understood what I was getting myself into.
P4: I contacted the research team and spoke to the trial
team when I went home, I felt this was a brilliant service.
When you sit in a clinic environment you definitely feel on
the spot and though there were a number a questions going
through my mind, in clinic I did not feel I could make a deci-
sion. But when I went home spoke to my husband and then
contacted the trial team I felt more confident.
P6: I think this trial did not look so complicated. Yes, it is
an open trial and that’s fine in my eyes…at least I know what I
am going to be taking. The researchers were thorough and
they were easily contactable. The were able to listen to my
concerns and really took a few of my suggestions which made
feel like my voice was valued and I wasn’t another trial
number.
With this study being a feasibility study, many of the par-
ticipants were free to voice their views on the protocol, design
Table 2 Background characteristics of participants
Characteristics of participants Total n = 22 (%)
Age < 65 years 15(68%)
≥ 65 years 7(14%)




Parity ≤ 2 12(54%)
> 2 10(50%)
BMI (mg/kg2) Mean (SD) 28.1
Maximum stage of prolapse Stage I 3(14%)
Stage II 9(41%)
Stage III/IV 10(45%)






and access to research team. These women felt part of the
research team that shaped the study from a patient’s point of
view. This even led two of participants becoming part of the
patient and public involvement (PPI) group.
Theme 3: Senior clinician input and collaboration
between the research and clinical teams
The recruitment process itself is often complex and involves
several linked activities performed by clinical and research
staff within and between different centres. We found that the
women who participated in the trial felt that input from the
clinicians gave them a security and confidence in enrolling in
a randomised control study.
P20: I found that talking to the clinician made be more
confident in the trial. She seemed to explain the ins and outs
of this trial. She helped understand what they were looking for
and why they were conducting the clinical trial. I trust the
clinical team; I mean they were the ones that took my symp-
toms seriously and I am finally being offered some kind of
surgery.
P15: The clinician really understood my condition; she
explained what was happening and the reason why I am prob-
ably having these symptoms. I guess this oestrogen might
help; that’s if I get that and if not then I am only being offered
what the rest the women with my condition are receiving on
the NHS.
Two-step approach
The researchers in this study screened the GP referral letters
and were able to identify potential women who could be in-
vited to participate in the study. The potential women were
sent patient information leaflets prior to them attending their
clinic appointments. This process assisted in preparing wom-
en regarding the clinical discussion and the clinical trial.
P2: I received a leaflet along with my clinic letter; I was
able to read through this prior to me attending this appoint-
ment. This leaflet was quite helpful and I was able to identify
many of my symptoms from just reading the leaflet. I felt more
confident; I knew I was attending the right clinic. I did read
about the trial as well; I was able to chat with my husband
about the study and ask a few more questions to the clinician
regarding it.
P7: I think this method of sending the details about the
study is helpful; it really saves time. I had time to think about
the study and I was able to make up my mind regarding
participation.
P14: I had loads of questions before I met the doctor, I even
wrote my queries on the leaflet. You need the time to think
about these things.
P17: I knew I was in the right place, I took my time decid-
ing whether I should participate. I read the information and
spoke to the clinician. I went home and then after discussing
with my family, I was able to contact the trial team and in-
formed them that I wanted to participate. I think it’s easier to
make up your mind when you are in your own home. Loads of
things went through my head when I was in clinic. We talked
about so many things, the surgery and the study.
Barriers to recruitment
Theme 4: Uncertainty
Themajor barrier to this study was the uncertainty of the study
product. The women who declined participation expressed
that they had a fear of experimentation and were concerned
of developing cancer. The number of discrepancies regarding
hormone replacement therapy fuelled this uncertainty.
Participants felt that their GPs were not confident in prescrib-
ing long-term hormone replacement therapy. Few participants
did not like to be “a guniea pig” in the process of the trial. The
Table 3 Summary of results
Facilitating factors to recruitment Barriers to recruitment
Altruism Uncertainty of treatment proposed
Simplicity of trial protocol Logistical factors—number of clinic appointments, parking
charges,transport dependence, leave from work
Clear and succinct patient information leaflets False perception of delay in receiving treatment if
participates in clinical trial
Easy accessibility to research teams via contact
telephone numbers and email addresses
Time constraints for patients
Active clinician input and collaboration with trial
units
Trivialisation of condition by primary care
Screening GP referral forms prior to clinic
appointments
Sending information leaflets to potential
participants before the clinic appointment
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conflicting information that they have received in the past with
regard to HRT made them worry about participation.
P14: I am not sure about hormone replacement; I had
spoken with my GP on a previous occasion regarding taking
oestrogen replacement and he did not want me to have ther-
apy for long term.
P10: I worry about developing cancer; I know this is a low
dose but who knows? Why would you want to put yourself in
such a position?
P3: This is conflicting information; you hear about the ill
effects of HRT and its relation with cancers like breast. I am
here for is being described as a chronic problem; if the sur-
gery can fix my prolapse why would I take any other medica-
tion? I would be quite anxious of developing any side effects.
Theme 5:Logistic factors
There were various logistical factors that were highlighted by
the women who felt that inhibited them for participating in the
trial.
P20: Coming to clinic appointments are really very diffi-
cult for me; I need my daughter to be available to bring me to
the clinic appointments. I do not want to be more of a burden
to her. I guess the lesser appointments the better.
P16: The parking charges in this hospital are really ridic-
ulous; I mean if I participate it would mean that I would
probably be here longer and if participation would wave these
charges perhaps I would consider participating.
P14: So many clinic appointments; I think the lesser time I
am at the hospital the better! I think I am always in the hos-
pital and lesser at home (laughs).
P17: I need to be there for my husband; he needs round the
clock care. I would not have come to this clinic; it has only
been because I started to have some bleeding that I did come
to this appointment. I would have just continued to ignore my
symptoms otherwise. I do not think I can possibly participate
at this point in my life; there is just too much going on.
Theme 6: Time between intervention and surgery
As per the study protocol, after randomisation participants in
the intervention arm were requested to commence medication
for a period of 6 weeks prior to their surgery. Some of the
women who were approached felt that they did not want to
wait for approximately 6–8 weeks for surgery. These women
perceived that time between commencing the investigational
product and surgery was a delaying factor and thought this
would disadvantage them on the waiting list for surgery.
P6: I was told that I require surgery; I do not want to wait
for another 2 months until I have surgery.
P15: I have put with these symptoms far too long, I would
just like to get on and have the surgery now. I think I have
postponed my treatment far too long; I think if I do participate
I will just be delaying the process.
Theme 7: Trivialisation of the condition
During the interview process, many women voiced their
thoughts regarding their condition and symptoms. De-
prioritisation of their own symptoms for several years before
they presented to medical team was recognised as a theme
among the women. Some felt embarrassed to come forward
while others felt regret for leaving their symptoms for so long.
Interestingly, some women were not self-aware of the wors-
ening of their condition. They were not sure what impact
prolapse could have on their bladder or bowel. The recogni-
tion of these worsening symptoms would assist the women
and their GPs for a referral to tertiary care.
P4: I went to my GP years ago and at that point she did not
say that my prolapse would worsen; all she said was to do
pelvic floor exercise. I think doctors have been telling me to do
this since I had my son nearly 30 years ago. I did not realise I
would need a surgery.
P8: I always had symptoms of prolapse and in fact I was so
embarrassed; I avoided going to the gym I was so worried I
would leak or others could notice my prolapse. Everyone said
it was part of ageing process…maybe I should have gone to
the doctor earlier.
P10: I am so irritated I always kept voicing my concern
with my GP. I do not think any one examined me in the past.
Now I am being told that I would require surgery. I just want
to get the surgery over with. I wish some had paid more
attention to my symptoms earlier.
The initial and emerging codes have been complied in
Table 4.
Discussion
We have sought to produce an understanding of 22 individ-
uals with POP and their experience within the trial and their
decisions making process as to what compelled them to take
part or refuse participation in the trial. We have demonstrated
that there was considerable variation among our participants,
but there were some strong common themes as well without
downplaying the uniqueness of each person’s view.
This study has helped us to understand factors that would
be likely to motivate or detract from patient participation and
retention within our planned trial. The factors that we identi-
fied were part of procedural, communication and resource
issues. The minimum contact must have a very specific struc-
ture and the research team must follow the structured guide-
lines until the woman feels sufficiently comfortable. There
must be a minimum adherence plan for the entire multicentre
clinical trial in the developmental stages of the trial [10].
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During the trial, researchers should be perceptive to the
feedback and information received from patients at the time
of recruitment. Despite numerous strategies present in the lit-
erature, gaps remain. Gul and Ali [11] identified that the ma-
jority of recommended interventions for enhancing the recruit-
ment and in clinical studies are ‘piecemeal’ and take little
account of how local practices of recruitment work influence
the effectiveness of such interventions [11].
Taking part in research is a complex decision. Multiple
factors play a role in decision-making. Altruism may have
existed in many participants and is seen across all clinical
studies [12]; however, in this group there was also an element
of their symptoms finally receiving recognition and acknowl-
edgement of a problem, which was ultimately taken seriously
when they enrolled into the trial. The majority felt that their
symptoms had been trivialised in the past. They voiced the
need for forums for women to talk openly about POP and
welcomed research in this area. Prolapse symptoms hindered
their quality of life and with an ageing population, there are
necessities to not only prolong life expectancy but equally
importance to quality of life. Participants experienced barriers
to trial participation including additional demands such as
attending appointments and associated time, effort or financial
costs, discomfort associated with trial procedures, the risk of
not being allocated to their preferred treatment and uncertain
outcomes. Likewise, Fogel et al. reported burdens including
potential side effects from treatment, additional tests that
would have to be endured, financial concerns (including loss
of job support and work disruption) and a general worry about
the unknown future, including whether or not the study drug
assigned would be beneficial [13, 14]. Sometimes patients are
not presented with a clear rationale for why their participation
is important and receive minimal feedback.
Women who received the leaflets prior to coming to their
designated clinic appointment found it easier to make their
decision on trial participation. This two-step approach of
Table 4 Coding index
Themes Initial categories
Clarity in information Trial teams gave maximum information
Individualised their concerns
Easy to understand
Not very complex patient information leaflet
Faith in clinical teams
Co-ordination between clinical and research teams
Timing of approach and environment Two step approach
Given enough time
Ability to contact trial teams
Easier to make a decision at home
Dedicated clinics for the trial purposes
Opportunities to ask questions
Acceptability of study design Understand the process of randomisation
Recall the design
Understand and maintain equipoise
Uncertainty Fear of cancer
Varied information online
Unpredictable outcomes
Concerns of side effects
Logistical concerns Dependent on family and friends
No monetary incentives
Timing between intervention and surgery
Other co-morbidities
Multiple appointments
Trivialisation Let down by clinical team
Prioritising other family issues over symptoms
Carer for family members
Embarrassed by the condition/ symptoms
Ageing process
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screening potential participants and sending out information
to the women prior to as well as having dedicated clinics for
potential participants gave the optimum time for women to
think over their options [15]. Screening patient records, iden-
tifying eligible patients, preparing recruitment material and
ensuring that the relevant clinicians were informed about the
study, were useful strategies practised by the research teams.
Similar strategies are echoed in various other clinical trials as
well [16, 17]. Chhatre et al. found that contacting potential
participant prior to clinical appointment helped streamline
the recruitment process [18]. Furthermore, an easily accessible
research team and the quality of information provided to these
patients gave the women an added confidence not only with
the clinician but with the research team as well.
The practicalities and co-ordination of balanced informa-
tion provision for patients about both treatments can be chal-
lenging. Clinicians may be comfortable explaining interven-
tions they routinely deliver but theymaywell be less confident
conveying the effectiveness of treatments outside their spe-
cialist remit. However, the research team were able to main-
tain equipoise better than the clinicians in informing patients
of the treatment choices. The research team at several points
had anxiety regarding the eligibility of women into the study.
In the LOTUS trial there were a few patients who were
flagged at multi-disciplinary team (MDT) meetings as poten-
tially eligible for the trial. These decisions were shared between
the clinical and research team and this assisted in giving the
research team confidence in having an open conversation with
the potential participant. The research team were given training
and assisted by clinicians to provide similar clinical message to
all involved participants through their journey in the trial.
Clinicians who maintained ongoing involvement with clinical
studies and positive relationship with the research staff and
accessiblity to the participants generated trust and together
helped the recruitment and retention efforts. Studies report that
up to 76% of patients expected their physician to alert them
about appropriate clinical trials and that physician referral was
one of the most useful recruitment strategy [19, 20].
This team approach enhanced the patient’s final under-
standing of the study as well maintaining equipoise and there-
fore ultimately increasing the likelihood of participation and
randomisation [21]. Similar MDT meetings are in practise in
cancer studies and they have found similar results [22].
Strengths
This is one of the few urogynaecology studies that looked at
the complexities in decision-making in women with prolapse
prior to embarking on clinical trials. The study has brought out
themes that are relevant when planning studies for POP. We
were able to identify the factors that facilitate and detract
women from participation. We gained insight into the
women’s experience and thereby were able to tailor the
consenting process. It highlighted the individual differences
and the desire for information.
The suggestions voiced by the participants were taken into
consideration and helped in framing a definitive trial that was
more patient friendly. Two of the women agreed to be part of
the patient and public involvement group for the proposed
definitive trial.
Limitations
The views obtained from a small cohort of women who par-
ticipated in the LOTUS trial. We obtained saturation with a
small sample size. However, the research teams did explore
and ultimately interviewed 22 women individually and a fo-
cused group interview to ensure and verify the emerging
themes from individual themes. We do acknowledge there
were other women in the trial who participated who may have
had unique views and reasons for participation in the trial. In
addition it is always challenging to distinguish between vari-
ous personality types. The study was open label and therefore
this could have influenced patient’s experience through the
trial process. Some of the themes that emerged were limited
to the trial itself and certain elements may not be transferrable
outside this setting.
Conclusion
The benefits of RCTs have been universally appreciated.
However, RCTs need to be more sensitive to women’s views
and understanding of their trial journey.
From this qualitative study, the researchers found that fac-
tors that enhanced participation were maintenance of simplic-
ity in patient leaflets, easy accessibility to research teams and
providing clarity in information disseminated, devoid of med-
ical jargon. The barriers to recruitment were uncertainty re-
garding the investigational product, logistical elements such
as physically attending multiple appointments, time con-
straints and false patient perception of delay in receiving treat-
ment if participating in a clinical trial.
These themes identified in this study will help shape a more
efficient and productive definitive study. For successful com-
pletion of clinical trials, future vaginal prolapse studies should
design their trials keeping the woman’s point of view as par-
amount importance.
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